Rocket Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

De CEO Rocket Pharmaceuticals' is Gaurav Shah, benoemd in Jan2018, heeft een ambtstermijn van 6.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 8.01M, bestaande uit 7.8% salaris en 92.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.24% van de aandelen van het bedrijf, ter waarde $ 20.77M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.1 jaar en 6.8 jaar.

Belangrijke informatie

Gaurav Shah

Algemeen directeur

US$8.0m

Totale compensatie

Percentage CEO-salaris	7.8%
Dienstverband CEO	6.8yrs
Eigendom CEO	1.2%
Management gemiddelde ambtstermijn	3.1yrs
Gemiddelde ambtstermijn bestuur	6.8yrs

Recente managementupdates

Recent updates

We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely

Jun 09

Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade)

Apr 05

Rocket Pharmaceuticals' Promising Path In Gene Therapy

Mar 01

Companies Like Rocket Pharmaceuticals (NASDAQ:RCKT) Are In A Position To Invest In Growth

Nov 07

Rocket Pharmaceuticals slides over 6% after hours on $100M stock offering

Oct 03

Rocket Pharmaceuticals: Updates To Thesis, Clinical Momentum Continues To Accelerate

Aug 25

We're Not Very Worried About Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Rate

Jul 22

Rocket Pharmaceuticals an outperform at Raymond James on gene therapy programs

Jul 08

Rocket Pharma: Poised For Growth In The Rare Disease Space

Jun 30

Rocket Pharmaceuticals: A Struggling Company With Long-Term Upside

Jan 30

We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely

Nov 09

Rocket Pharmaceuticals Stock Forecast: Can It Rebound To $50 Levels? A Resounding Yes

Oct 01

Rocket earns Evercore nod after positive data for rare genetic disease

Dec 17

Rocket Pharma +33.6% after positive early data in Danon disease Phase 1 trial

Dec 09

Analyse CEO-vergoeding

Hoe is Gaurav Shah's beloning veranderd ten opzichte van Rocket Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$253m
Mar 31 2024	n/a	n/a	-US$249m
Dec 31 2023	US$8m	US$625k	-US$246m
Sep 30 2023	n/a	n/a	-US$253m
Jun 30 2023	n/a	n/a	-US$249m
Mar 31 2023	n/a	n/a	-US$237m
Dec 31 2022	US$7m	US$598k	-US$222m
Sep 30 2022	n/a	n/a	-US$199m
Jun 30 2022	n/a	n/a	-US$192m
Mar 31 2022	n/a	n/a	-US$172m
Dec 31 2021	US$8m	US$590k	-US$169m
Sep 30 2021	n/a	n/a	-US$186m
Jun 30 2021	n/a	n/a	-US$165m
Mar 31 2021	n/a	n/a	-US$155m
Dec 31 2020	US$7m	US$540k	-US$140m
Sep 30 2020	n/a	n/a	-US$99m
Jun 30 2020	n/a	n/a	-US$89m
Mar 31 2020	n/a	n/a	-US$82m
Dec 31 2019	US$4m	US$480k	-US$77m
Sep 30 2019	n/a	n/a	-US$85m
Jun 30 2019	n/a	n/a	-US$82m
Mar 31 2019	n/a	n/a	-US$79m
Dec 31 2018	US$6m	US$414k	-US$75m

Compensatie versus markt: De totale vergoeding ($USD 8.01M ) Gaurav } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.54M ).

Compensatie versus inkomsten: De vergoeding van Gaurav is gestegen terwijl het bedrijf verliesgevend is.

CEO

Gaurav Shah (49 yo)

6.8yrs

Tenure

US$8,013,553

Compensatie

Dr. Gaurav D. Shah, M.D., has been an Independent Director at Talaris Therapeutics, Inc. since December 2020. He serves as the Chief Executive Officer and Director of Rocket Pharmaceuticals, Ltd since Janu...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Gaurav Shah	CEO & Director	6.8yrs	US$8.01m	1.24% $ 19.7m
Kinnari Patel	Head of R&D	6.8yrs	US$4.85m	0.44% $ 7.0m
Mayo Pujols	Chief Technical Officer	2.3yrs	US$4.38m	0.062% $ 990.4k
Jonathan Schwartz	Chief Medical & Gene Therapy Officer	6.8yrs	US$3.16m	0.11% $ 1.7m
Aaron Ondrey	Chief Financial Officer	less than a year	geen gegevens	geen gegevens
Martin Wilson	General Counsel	2.9yrs	US$1.56m	0.071% $ 1.1m
Kevin Giordano	Director of Corporate Communications	no data	geen gegevens	geen gegevens
Isabel Carmona	Chief People Officer	3.1yrs	geen gegevens	geen gegevens
Gayatri Rao	Senior VP of Clinical Safety & Chief Regulatory Officer	4.5yrs	geen gegevens	geen gegevens
Raj Prabhakar	Chief Business Officer	no data	US$2.82m	0% $ 0
Carlos Martin	Chief Commercial Operations & Revenue Officer	less than a year	geen gegevens	geen gegevens

3.1yrs

Gemiddelde duur

49yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van RCKT wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Gaurav Shah	CEO & Director	6.8yrs	US$8.01m	1.24% $ 19.7m
David Southwell	Independent Director	10.2yrs	US$399.99k	0.13% $ 2.0m
Pedro Granadillo	Independent Director	6.8yrs	US$429.98k	0% $ 0
Carsten Boess	Independent Director	8.8yrs	US$427.49k	0% $ 0
Mikael Dolsten	Independent Director	less than a year	geen gegevens	geen gegevens
Roderick Tze Wong	Chairman of the Board	6.8yrs	US$409.99k	0.059% $ 937.8k
Naveen Yalamanchi	Independent Director	6.8yrs	US$417.49k	0.13% $ 2.0m
Fady Malik	Independent Non-Executive Director	2.6yrs	US$399.99k	0% $ 0
Elisabeth Bjork	Independent Director	4.5yrs	US$409.99k	0% $ 0
Gotham Makker	Director	6.8yrs	US$399.99k	0.22% $ 3.5m
Robert Woods	Independent Non- Executive Director	less than a year	US$568.70k	geen gegevens

6.8yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van RCKT wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.8 jaar).

Rocket Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Rocket Pharmaceuticals, Inc. Appoints Mikael Dolsten to the Board

CEO & Director recently sold US$229k worth of stock

CEO & Director notifies of intention to sell stock

Rocket Pharmaceuticals, Inc., Annual General Meeting, Jun 13, 2024

Independent Director notifies of intention to sell stock

Insider recently sold US$309k worth of stock

Recent updates

Will Rocket Pharmaceuticals (NASDAQ:RCKT) Spend Its Cash Wisely?

Rocket Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease

Rocket Pharmaceuticals: 2 Gene Therapy Candidates Anticipating Near-Term Review

Rocket Pharmaceuticals, Inc. Appoints Mikael Dolsten to the Board

Rocket Pharmaceuticals, Inc. Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel)

Rocket Pharmaceuticals: CRL For Kresladi Unwelcome, But Likely A Quick Fix

We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely

CEO & Director recently sold US$229k worth of stock

CEO & Director notifies of intention to sell stock

Consensus revenue estimates fall by 11%

Rocket Pharmaceuticals Presents Positive Data from Lv Hematology Portfolio At the 27Th Annual Meeting of the American Society of Gene and Cell Therapy (Asgct)

New minor risk - Profitability

Rocket Pharmaceuticals, Inc., Annual General Meeting, Jun 13, 2024

Independent Director notifies of intention to sell stock

Insider recently sold US$309k worth of stock

Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade)

Rocket Pharmaceuticals, Inc. Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia

Rocket Pharmaceuticals, Inc. Announces Executive Appointments

Consensus revenue estimates decrease by 57%, EPS upgraded

VP, Senior Controller notifies of intention to sell stock

Rocket Pharmaceuticals' Promising Path In Gene Therapy

No longer forecast to breakeven

New minor risk - Insider selling

CEO & Director recently sold US$605k worth of stock

CEO & Director notifies of intention to sell stock

Rocket Pharmaceuticals, Inc. Announces Update on Fda Review Timeline of Kresladi™ (Marnetegragene Autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (Lad-I)

New minor risk - Profitability

Forecast to breakeven in 2026

Rocket Pharmaceuticals, Inc. Appoints R. Keith Woods as Independent, Non-Executive Director

New major risk - Revenue and earnings growth

New minor risk - Profitability

Rocket Pharmaceuticals, Inc. Announces Fda Acceptance of Biologics License Application with Priority Review for Rp-L201 (Marnetegragene Autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (Lad-I)

Rocket Pharmaceuticals Receives European Medicines Agency (Ema) Priority Medicines (Prime) Designation for RP-A501 Gene Therapy for Danon Disease

CEO & Director recently sold US$88k worth of stock

Rocket Pharmaceuticals, Inc. Announces FDA Clearance of IND for Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy (ACM)

Insufficient new directors

Insider notifies of intention to sell stock

Consensus revenue estimates fall by 95%

CEO & Director notifies of intention to sell stock

Insider recently sold US$68k worth of stock

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease

Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM

Rocket Pharmaceuticals, Inc. Provides Update on Anticipated Registration Path for RP-A501 in Danon Disease Following End-Of-Phase 1 FDA Meeting

Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) completed the acquisition of Renovacor, Inc. (NYSEAM:RCOR) from RTW Investments, LP, Chardan Investments 2, LLC and others,

Now 23% undervalued

Companies Like Rocket Pharmaceuticals (NASDAQ:RCKT) Are In A Position To Invest In Growth

Rocket Pharmaceuticals, Inc. Announces Presentations Highlighting Lentiviral Gene Therapies at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)

Rocket Pharmaceuticals slides over 6% after hours on $100M stock offering

Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022

Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) entered into a definitive agreement to acquire Renovacor, Inc. (NYSEAM:RCOR) from RTW Investments, LP and others for $46.7 million.

Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) entered into a definitive agreement to acquire Renovacor, Inc. (NYSEAM:RCOR) from RTW Investments, LP and others for $46.7 million.

Rocket Pharmaceuticals: Updates To Thesis, Clinical Momentum Continues To Accelerate

Rocket Pharmaceuticals, Inc. Appoints Mayo Pujols as Chief Technical Officer and Executive Vice President

Price target decreased to US$53.18

We're Not Very Worried About Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Rate

Rocket Pharmaceuticals an outperform at Raymond James on gene therapy programs

Rocket Pharma: Poised For Growth In The Rare Disease Space

Rocket Pharmaceuticals Presents Positive Top-Line Data from Severe Leukocyte Adhesion Deficiency-I Program At the 25Th Annual Meeting of the American Society of Gene and Cell Therapy (Asgct)

Rocket Pharmaceuticals, Inc. Presents Positive Clinical Data from Danon Disease, Fanconi Anemia and Pyruvate Kinase Deficiency Programs at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Price target decreased to US$58.50

Rocket Pharmaceuticals, Inc., Annual General Meeting, Jun 13, 2022

Rocket Pharmaceuticals Appoints Fady Malik to Board of Directors

Rocket Pharmaceuticals Appoints Jessie Yeung as Vice President of Investor Relations and Corporate Finance

Price target decreased to US$63.56

Consensus forecasts updated

CEO & Director recently bought US$382k worth of stock

Rocket Pharmaceuticals: A Struggling Company With Long-Term Upside

Rocket Pharmaceuticals Presents Positive Clinical Data from Company’s Lentiviral Gene Therapies for Treatment of Fanconi Anemia, LAD-I and PKD at the 63rd American Society of Hematology (ASH) Annual Meeting

We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely